Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Equity Average (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Equity Average data on record, last reported at $339.3 million in Q4 2025.

  • For Q4 2025, Equity Average rose 46.86% year-over-year to $339.3 million; the TTM value through Dec 2025 reached $339.3 million, up 46.86%, while the annual FY2025 figure was $284.0 million, 34.74% up from the prior year.
  • Equity Average reached $339.3 million in Q4 2025 per TARS's latest filing, up from $333.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $339.3 million in Q4 2025 and bottomed at $158.0 million in Q1 2022.
  • Average Equity Average over 5 years is $223.7 million, with a median of $201.5 million recorded in 2022.
  • Peak YoY movement for Equity Average: soared 2078.11% in 2021, then fell 14.79% in 2023.
  • A 5-year view of Equity Average shows it stood at $172.9 million in 2021, then grew by 14.36% to $197.8 million in 2022, then rose by 3.82% to $205.3 million in 2023, then increased by 12.51% to $231.0 million in 2024, then skyrocketed by 46.86% to $339.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $339.3 million in Q4 2025, $333.8 million in Q3 2025, and $337.5 million in Q2 2025.